Breaking News Instant updates and real-time market news.

BBBY

Bed Bath & Beyond

$12.26

-0.03 (-0.24%)

, LOW

Lowe's

$111.39

0.725 (0.66%)

10:19
10/15/19
10/15
10:19
10/15/19
10:19

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bed Bath & Beyond (BBBY) upgraded to Overweight from Sector Weight at KeyBanc with analyst Bradley Thomas saying his proprietary data suggests the company's same-store sales trends have been improving. 2. Lowe's (LOW) upgraded to Overweight from Neutral at Piper Jaffray with analyst Peter Keith saying the company's fundamentals look poised for acceleration in the second half of 2019 and 2020, "yet expectations seem modest." 3. Premier (PINC) upgraded to Buy from Hold at Canaccord with analyst Richard Close saying near-term fundamentals are lacking but believes the shares are cheap following its recent pullback. 4. Zealand Pharma (ZEAL) upgraded to Buy from Neutral at Goldman Sachs with analyst Graig Suvannavejh citing increased optimism on the company's pipeline and commercial execution for the upgrade. 5. Imperial Oil (IMO) upgraded to Neutral from Underperformer at CIBC. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

BBBY

Bed Bath & Beyond

$12.26

-0.03 (-0.24%)

LOW

Lowe's

$111.39

0.725 (0.66%)

PINC

Premier

$31.20

0.78 (2.56%)

ZEAL

Zealand Pharma

$27.53

4.28 (18.41%)

IMO

Imperial Oil

$24.41

0.165 (0.68%)

  • 05

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

BBBY Bed Bath & Beyond
$12.26

-0.03 (-0.24%)

10/14/19
KEYB
10/14/19
UPGRADE
Target $18
KEYB
Overweight
Bed Bath & Beyond upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Bradley Thomas upgraded Bed Bath & Beyond to Overweight from Sector Weight with a $18 price target.
10/10/19
10/10/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Apple (AAPL) upgraded to Buy from Neutral at Longbow with analyst Shawn Harrison saying his contacts, who previously gave him initial conservative forecasts for up to a 10% year-over-year decline in iPhone production in the calendar third quarter, now see flat production in the period of Apple's fiscal fourth quarter. 2. Qorvo (QRVO) and Skyworks (SWKS) upgraded to Outperform from Market Perform at Cowen. 3. Allegheny Technologies (ATI) upgraded to Buy from Neutral at Goldman Sachs with analyst Matthew Korn saying Allegheny is one of few stocks in the sector with sales growth that does not depend on a commodity price recovery. 4. Bed Bath & Beyond (BBBY) upgraded to Outperform from Market Perform at Telsey Advisory. 5. Morgan Stanley (MS) upgraded to Buy from Hold at Sandler O'Neill with analyst Jeffery Harte citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage click here.
10/15/19
KEYB
10/15/19
UPGRADE
Target $18
KEYB
Overweight
KeyBanc upgrades Bed Bath & Beyond on 'sizable upside opportunity'
KeyBanc analyst Bradley Thomas last night upgraded Bed Bath & Beyond to Overweight from Sector Weight with an $18 price target. The retailer closed Monday down 68c, of 5%, to $12.30. The analyst's proprietary data suggests the company's same-store sales trends have been improving. Further, he believes new CEO Mark Tritton and his merchandising background should be a "strong fit" for Bed Bath's needs. In addition, asset sales or divestitures "could happen sooner rather than later" and could be material, while the stock's valuation points to a "sizable upside opportunity" with "relatively bearish sentiment baked in," contends Thomas. The analyst sees "several key reasons" to own shares of Bed Bath & Beyond.
10/10/19
MSCO
10/10/19
NO CHANGE
Target $12
MSCO
Equal Weight
Bed Bath CEO hiring could prompt short squeeze, says Morgan Stanley
Morgan Stanley analyst Simeon Gutman said selecting Mark Tritton, formerly of Target (TGT), was "a high quality hire" for Bed Bath & Beyond (BBBY) and "a clear win" that could prompt the stock to squeeze above his unchanged $12 price target in the near-term. However, he thinks concerns will linger and while the bull case may come back into focus over the longer-term, the execution risk remains high. Gutman keeps an Equal Weight rating on Bed Bath & Beyond shares.
LOW Lowe's
$111.39

0.725 (0.66%)

10/15/19
BOFA
10/15/19
NO CHANGE
BOFA
Advance Auto Parts added to US 1 List, Dover, Lowe's removed at BofA/Merrill
10/07/19
RAJA
10/07/19
INITIATION
RAJA
Market Perform
Lowe's assumed with a Market Perform at Raymond James
Raymond James analyst Matthew McClintock assumed coverage of Lowe's with a Market Perform rating, which is downgraded from Outperform under prior coverage. The analyst believes that the company has "substantial upside potential longer-term" but also warns that retail restructurings "always take longer to execute" than planned. McClintock adds that the goals under Lowe's restructuring plan will require "significant investments", which may negatively impact margin.
10/08/19
WOLF
10/08/19
DOWNGRADE
Target $118
WOLF
Peer Perform
Lowe's downgraded to Peer Perform from Outperform at Wolfe Research
Wolfe Research analyst Chris Bottiglieri assumed coverage on Lowe's with a Peer Perform rating from an Outperform rating and a $118 price target. The analyst said his near-term positive view is offset by long-term margin expectations and the potential for accelerated investments. Bottiglieri does not believe high expectations are reflected in valuation or estimates, and sees risks from an acceleration of tariffs that could lead to further pricing issues.
10/15/19
PIPR
10/15/19
UPGRADE
Target $130
PIPR
Overweight
Lowe's upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Peter Keith upgraded Lowe's to Overweight from Neutral with a price target of $130, up from $113. The company's fundamentals look poised for acceleration in the second half of 2019 and 2020, "yet expectations seem modest," Keith tells investors in a research note. The analyst's "extensive industry analysis" indicates the housing/home remodel backdrop will strengthen into the first half of 2020. Amidst this backdrop, Keith sees a path for accelerating comp growth and gross margin upside in 2020 for Lowe's. The stock's risk/reward looks "quite favorable," with over 40% upside potential versus 10% downside risk over the next 12 months, contends Keith.
PINC Premier
$31.20

0.78 (2.56%)

09/26/19
JEFF
09/26/19
NO CHANGE
Target $43
JEFF
Buy
Jefferies keeps Buy rating on Premier following short report
The potential for elevated client attrition in Premier' group purchasing organization business is back in the spotlight following a short report yesterday, Jefferies analyst Jason Plagman tells investors in a research note. In the near-term, the analyst believes Premier is actively discussing a mutually beneficial long-term contract with its largest client Acurity aimed at extending that relationship beyond September 2020. Longer term, he believes the company's combination of supply chain, technology, and advisory services "has created deep relationships that extend beyond procurement." Plagman keeps a Buy rating on Premier with a $43 price target.
09/26/19
BARD
09/26/19
NO CHANGE
Target $46
BARD
Outperform
Premier short report concerns around since its IPO, says Baird
Baird analyst Eric Coldwell noted Premier shares were lower following the release of a short report which he says rehashes concerns that have been around since its IPO six years ago. He said the short report takes doomsday scenarios to the extreme but he doubts the business model will fall off a cliff. Separately, Coldwell's enthusiasm has lessened recently but he maintains his Outperform rating and $46 price target on Premier shares.
10/15/19
ADAM
10/15/19
UPGRADE
Target $36
ADAM
Buy
Premier upgraded to Buy at Canaccord
As reported previously, Canaccord analyst Richard Close upgraded Premier to Buy from Hold . The analyst admitted near-term fundamentals are lacking but believes the shares are cheap following its recent pullback. He thinks the shares could see a bounce on any in-line earnings and guidance and believes the scales favor the upside heading into its Q1 report. Close maintained his $36 price target on Premier shares.
10/15/19
ADAM
10/15/19
UPGRADE
Target $36
ADAM
Buy
Premier upgraded to Buy from Hold at Canaccord
Canaccord Genuity analyst Richard Close upgraded Premier to Buy from Hold with a $36 price target.
ZEAL Zealand Pharma
$27.53

4.28 (18.41%)

09/19/19
GUGG
09/19/19
INITIATION
Target $84
GUGG
Buy
Guggenheim starts 'diamond in the rough' MyoKardia at Buy
Guggenheim analyst Etzer Darout started MyoKardia (MYOK) with a Buy rating, identifying the company and Zealand Pharma (ZEAL) as "diamonds in the rough" that are focused on therapies for cardiovascular and metabolic disorders and targeting therapeutic segments where patients are more homogenous and/or targets are validated. He currently value MYOK's mavacamten lead program in obstructive hypertrophic cardiomyopathy, or oHCM, at $63 per share with a 75% probability of success, Darout noted in his initiation. He set a $84 price target on MyoKardia shares.
10/15/19
GSCO
10/15/19
UPGRADE
Target $41
GSCO
Buy
Zealand Pharma upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Graig Suvannavejh upgraded Zealand Pharma to Buy from Neutral with a $41 price target. The analyst cites increased optimism on the company's pipeline and commercial execution for the upgrade. He raised his revenue estimates for Zealand's two keys products, glepaglutide and dasiglucagon HypoPal. With new senior leadership in place, Zealand Pharma "finds itself on the cusp of transforming" into a commercial stage company over the next few years, Suvannavejh tells investors in a research note. The analyst's 12-month price target implies 70% upside in the shares.
09/20/19
09/20/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Roku (ROKU) initiated with a Sell at Pivotal Research. 2. Carvana (CVNA) initiated with an Outperform at Oppenheimer. 3. Zealand Pharma (ZEAL) and MyoKardia (MYOK) were initiated with a Buy at Guggenheim. 4. Wayfair (W) initiated with a Sell at Berenberg. 5. Eton Pharmaceuticals (ETON) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/19/19
GUGG
09/19/19
INITIATION
GUGG
Buy
Zealand Pharma initiated with a Buy at Guggenheim
Guggenheim analyst Etzer Darout started Zealand Pharma (ZEAL) with a Buy rating, identifying the company and MyoKardia (MYOK) as "diamonds in the rough" that are focused on therapies for cardiovascular and metabolic disorders and targeting therapeutic segments where patients are more homogenous and/or targets are validated. He sees Zealand's major near-term driver being gleplagutide's pivotal data in patients with short bowel syndrome, due in the second half of 2020. He has a price target of DKK 235 on the local shares of ZEAL-DK, noting that Guggenheim is terminating coverage of the ADR shares of Zealand.
IMO Imperial Oil
$24.41

0.165 (0.68%)

10/15/19
CIBC
10/15/19
UPGRADE
CIBC
Neutral
Imperial Oil upgraded to Neutral from Underperformer at CIBC
CIBC analyst Jon Morrison upgraded Imperial Oil to Neutral from Underperformer with a price target of C$38, up from C$37.
10/07/19
SBSH
10/07/19
DOWNGRADE
SBSH
Sell
Imperial Oil downgraded to Sell from Neutral at Citi
Citi analyst Prashant Rao downgraded Imperial Oil to Sell from Neutral saying the shares at current levels are more than fully valuing the company's production ramp and expected free cash flow generation over the next two years.
10/07/19
ALTA
10/07/19
UPGRADE
ALTA
Sector Perform
Imperial Oil upgraded to Sector Perform from Underperform at Alta
Alta analyst Nicholas Lupick upgraded Imperial Oil to Sector Perform from Underperform with a C$40 price target.
09/30/19
MITR
09/30/19
DOWNGRADE
MITR
Reduce
Imperial Oil downgraded to Reduce from Hold at GMP Securities
GMP Securities analyst Michael Dunn downgraded Imperial Oil to Reduce from Hold and lowered his target price to $31 from $33 ahead of the company's Q3 earnings report on November 1. The analyst said his current macro outlook for Imperial is "quite unfavorable" due to its Chemicals business seeing weaker margins, production curtailments hurting its ability to produce Kearl at peak rates, "relatively tight" Canadian crude oil differentials against Brent crude oil, and a West Texas Intermediate oil and Brent strip that implies lower oil prices year-over-year for 2020.

TODAY'S FREE FLY STORIES

WFC

Wells Fargo

$53.80

0.3 (0.56%)

, AAPL

Apple

$265.73

3.07 (1.17%)

10:01
11/16/19
11/16
10:01
11/16/19
10:01
Periodicals
Berkshire Hathaway inactive with record cash hoard, Barron's says »

Berkshire Hathaway…

WFC

Wells Fargo

$53.80

0.3 (0.56%)

AAPL

Apple

$265.73

3.07 (1.17%)

OXY

Occidental Petroleum

$38.94

1.18 (3.13%)

BRK.B

Berkshire Hathaway

$219.74

0.38 (0.17%)

BRK.A

Berkshire Hathaway

$329,361.11

266.11 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

DIS

Disney

$144.63

-2.56 (-1.74%)

09:43
11/16/19
11/16
09:43
11/16/19
09:43
Periodicals
Disney+ may not be able to hold onto huge number of subs, Barron's says »

While Disney's (DIS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$112.11

2.9 (2.66%)

09:27
11/16/19
11/16
09:27
11/16/19
09:27
Periodicals
Medtronic shares 'could rise even more,' Barron's says »

Barron's recommended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BR

Broadridge

$119.80

0.485 (0.41%)

09:18
11/16/19
11/16
09:18
11/16/19
09:18
Periodicals
Broadridge a defensive name that can withstand slowdown, Barron's says »

Broadridge Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$193.95

-0.02 (-0.01%)

, MDT

Medtronic

$112.11

2.9 (2.66%)

09:07
11/16/19
11/16
09:07
11/16/19
09:07
Periodicals
Barron's suggests dividend stocks for retirement savers »

In this week's…

MCD

McDonald's

$193.95

-0.02 (-0.01%)

MDT

Medtronic

$112.11

2.9 (2.66%)

KO

Coca-Cola

$52.67

0.03 (0.06%)

PRU

Prudential

$93.61

0.82 (0.88%)

SYF

Synchrony

$37.05

0.34 (0.93%)

KEY

KeyCorp

$18.96

0.1 (0.53%)

T

AT&T

$39.49

0.53 (1.36%)

AMGN

Amgen

$220.84

2.29 (1.05%)

CSCO

Cisco

$45.10

0.18 (0.40%)

RCL

Royal Caribbean

$117.91

2.69 (2.33%)

MRK

Merck

$84.89

0.33 (0.39%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

JPM

JPMorgan

$129.51

0.83 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 02

    Dec

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 14

    Jan

  • 21

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 29

    Jan

  • 05

    Feb

  • 12

    Feb

  • 14

    Mar

AMZN

Amazon.com

$1,737.49

-17.22 (-0.98%)

, MSFT

Microsoft

$149.95

1.89 (1.28%)

08:54
11/16/19
11/16
08:54
11/16/19
08:54
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,737.49

-17.22 (-0.98%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

AAPL

Apple

$265.73

3.07 (1.17%)

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

THC

Tenet

$30.55

1.08 (3.66%)

GM

General Motors

$36.87

0.07 (0.19%)

FCAU

Fiat Chrysler

$16.02

0.04 (0.25%)

TM

Toyota

$144.29

1.16 (0.81%)

F

Ford

$8.96

0.16 (1.82%)

HMC

Honda

$28.99

0.155 (0.54%)

VWAGY

Volkswagen

$0.00

(0.00%)

BMWYY

BMW

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 04

    Feb

  • 06

    Feb

MDCO

The Medicines Co.

$51.92

1.03 (2.02%)

04:55
11/16/19
11/16
04:55
11/16/19
04:55
Conference/Events
Roth Capital pharmaceuticals analysts to hold a luncheon »

Analysts host Dr. John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

CVET

Covetrus

$14.93

1.44 (10.67%)

18:41
11/15/19
11/15
18:41
11/15/19
18:41
Hot Stocks
Covetrus CEO: We're a leader in the humanization of pets »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSK

Comcast

$0.00

(0.00%)

, CMCSA

Comcast

$44.54

-0.93 (-2.05%)

18:02
11/15/19
11/15
18:02
11/15/19
18:02
Hot Stocks
Viacom extends cable deal for 'The Office' through 2025 »

Viacom (VIA) announced…

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$44.54

-0.93 (-2.05%)

VIAB

Viacom

$23.07

0.59 (2.62%)

VIA

Viacom

$26.59

1.28 (5.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CWK

Cushman & Wakefield

$19.10

0.1 (0.53%)

17:48
11/15/19
11/15
17:48
11/15/19
17:48
Hot Stocks
Cushman & Wakefield CEO sells 84.6K share of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

LMT

Lockheed Martin

$393.52

3.305 (0.85%)

17:39
11/15/19
11/15
17:39
11/15/19
17:39
Hot Stocks
Lockheed Martin awarded maximum $3.33B Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESCA

Escalade

$10.90

-0.09 (-0.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Escalade CEO Fetherman to retire »

Escalade announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.96

0.1 (0.78%)

, ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Eldorado, Caesars stockholders approve Eldorado acquisition of Caesars »

Eldorado Resorts (ERI)…

CZR

Caesars

$12.96

0.1 (0.78%)

ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EGRX

Eagle Pharmaceuticals

$57.24

0.55 (0.97%)

17:15
11/15/19
11/15
17:15
11/15/19
17:15
Syndicate
Breaking Syndicate news story on Eagle Pharmaceuticals »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$60.82

0.84 (1.40%)

17:11
11/15/19
11/15
17:11
11/15/19
17:11
Hot Stocks
Fabrinet President Gill sells 12.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

TEUM

Pareteum

$0.38

-0.0209 (-5.21%)

17:05
11/15/19
11/15
17:05
11/15/19
17:05
Hot Stocks
Pareteum receives noncompliance notice from Nasdaq »

Pareteum announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEXO

Hexo

$1.78

-0.1 (-5.32%)

17:00
11/15/19
11/15
17:00
11/15/19
17:00
Hot Stocks
Hexo was cannabis was being grown in unlicensed space at Niagara site »

HEXO Corp provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$220.84

2.29 (1.05%)

, CELG

Celgene

$110.02

-0.01 (-0.01%)

16:57
11/15/19
11/15
16:57
11/15/19
16:57
Hot Stocks
Bristol-Myers gets FTC clearance for Celgene acquisition »

Bristol-Myers Squibb…

AMGN

Amgen

$220.84

2.29 (1.05%)

CELG

Celgene

$110.02

-0.01 (-0.01%)

BMY

Bristol-Myers

$58.61

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 04

    Dec

  • 07

    Dec

  • 25

    Mar

  • 04

    Apr

RAVE

Rave Restaurant

$1.44

-0.79 (-35.43%)

16:47
11/15/19
11/15
16:47
11/15/19
16:47
Hot Stocks
BBRC Asset Management reports 6.6% passive stake in Rave Restaurant »

BBRC Asset Management …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHAP

Chaparral Energy

$0.89

-0.0521 (-5.52%)

16:46
11/15/19
11/15
16:46
11/15/19
16:46
Hot Stocks
Chaparral Energy receives continued listing standard notice from NYSE »

Chaparral Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

CI

Cigna

$196.08

6.41 (3.38%)

, CNC

Centene

$57.57

2.91 (5.32%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks closed out the…

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

NVDA

Nvidia

$204.12

-5.76 (-2.74%)

AMZN

Amazon.com

$1,739.33

-15.38 (-0.88%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

UAA

Under Armour

$17.78

0.65 (3.79%)

UA

Under Armour

$15.97

0.41 (2.64%)

AMRN

Amarin

$23.99

2.5 (11.63%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

GOOG

Alphabet

$1,334.01

21.82 (1.66%)

GOOGL

Alphabet Class A

$1,333.33

23.54 (1.80%)

ORCL

Oracle

$56.43

0.33 (0.59%)

RH

RH

$188.73

13.535 (7.73%)

QGEN

Qiagen

$40.56

3.255 (8.73%)

FTCH

Farfetch

$9.66

2.17 (28.97%)

THC

Tenet

$30.55

1.08 (3.66%)

TORC

resTORbio

$1.10

-6.83 (-86.13%)

ACB

Aurora Cannabis

$2.72

-0.57 (-17.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 28

    Dec

  • 06

    Jan

  • 21

    Jan

  • 06

    Feb

NYT

New York Times

$31.60

0.44 (1.41%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
New York Times CEO sells 66,000 class A common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

WEX

Wex

$200.52

4.61 (2.35%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
Wex director Morris sells 3K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.